This has led us to investigate the baseline clinical characteristics of patients with advanced BRCA1/2 mutation ovarian cancer, including the effects of platinum sensitivity as potential factors that may be used in the prediction of patients benefit to olaparib. The gene discussed is BRCA1; the disease is ovarian cancer.